HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Raises Price Target to $8
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Sean Lee maintains a 'Buy' rating on Plus Therapeutics (NASDAQ:PSTV) and raises the price target from $3.5 to $8.
June 30, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics' price target has been raised from $3.5 to $8 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Plus Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100